106 related articles for article (PubMed ID: 8000381)
1. Effects of fluidity and vesicle size on antitumor activity and myelosuppressive activity of liposomes loaded with daunorubicin.
Nagayasu A; Shimooka T; Kinouchi Y; Uchiyama K; Takeichi Y; Kiwada H
Biol Pharm Bull; 1994 Jul; 17(7):935-9. PubMed ID: 8000381
[TBL] [Abstract][Full Text] [Related]
2. Effect of vesicle size on in vivo release of daunorubicin from hydrogenated egg phosphatidylcholine-based liposomes into blood circulation.
Nagayasu A; Shimooka T; Kiwada H
Biol Pharm Bull; 1995 Jul; 18(7):1020-3. PubMed ID: 7581243
[TBL] [Abstract][Full Text] [Related]
3. Is control of distribution of liposomes between tumors and bone marrow possible?
Nagayasu A; Uchiyama K; Nishida T; Yamagiwa Y; Kawai Y; Kiwada H
Biochim Biophys Acta; 1996 Jan; 1278(1):29-34. PubMed ID: 8611603
[TBL] [Abstract][Full Text] [Related]
4. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes.
Bally MB; Nayar R; Masin D; Cullis PR; Mayer LD
Cancer Chemother Pharmacol; 1990; 27(1):13-9. PubMed ID: 2245488
[TBL] [Abstract][Full Text] [Related]
5. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.
Papagiannaros A; Hatziantoniou S; Dimas K; Papaioannou GT; Demetzos C
Biomed Pharmacother; 2006 Jan; 60(1):36-42. PubMed ID: 16271845
[TBL] [Abstract][Full Text] [Related]
6. [Effects of different phospholipids on the stabilities of doxorubicin liposomes in vitro and in vivo].
Wang L; Hou BG; Hou XP; Yu ML; Yang JS
Yao Xue Xue Bao; 2001 Jun; 36(6):444-7. PubMed ID: 12585130
[TBL] [Abstract][Full Text] [Related]
7. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals.
Ying X; Wen H; Lu WL; Du J; Guo J; Tian W; Men Y; Zhang Y; Li RJ; Yang TY; Shang DW; Lou JN; Zhang LR; Zhang Q
J Control Release; 2010 Jan; 141(2):183-92. PubMed ID: 19799948
[TBL] [Abstract][Full Text] [Related]
8. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of doxorubicin encapsulated in hexadecylphosphocholine (HePC) liposomes against human xenografts on Scid mice.
Papagiannaros A; Hatziantoniou S; Lelong-Rebel IH; Papaioannou GT; Dimas K; Demetzos C
In Vivo; 2006; 20(1):129-35. PubMed ID: 16433041
[TBL] [Abstract][Full Text] [Related]
10. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.
Papagiannaros A; Bories C; Demetzos C; Loiseau PM
Biomed Pharmacother; 2005 Dec; 59(10):545-50. PubMed ID: 16325367
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermia enhances tumor uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor.
van Bree C; Krooshoop JJ; Rietbroek RC; Kipp JB; Bakker PJ
Cancer Res; 1996 Feb; 56(3):563-8. PubMed ID: 8564972
[TBL] [Abstract][Full Text] [Related]
12. The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers.
Shao M; Sun SL; Li MH; Li BX; Yu H; Shen ZY; Ren YC; Hao ZF; Chang ND; Peng HS; Yang BF
J Liposome Res; 2012 Jun; 22(2):168-76. PubMed ID: 22428938
[TBL] [Abstract][Full Text] [Related]
13. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
Tardi P; Johnstone S; Harasym N; Xie S; Harasym T; Zisman N; Harvie P; Bermudes D; Mayer L
Leuk Res; 2009 Jan; 33(1):129-39. PubMed ID: 18676016
[TBL] [Abstract][Full Text] [Related]
14. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.
Lim WS; Tardi PG; Dos Santos N; Xie X; Fan M; Liboiron BD; Huang X; Harasym TO; Bermudes D; Mayer LD
Leuk Res; 2010 Sep; 34(9):1214-23. PubMed ID: 20138667
[TBL] [Abstract][Full Text] [Related]
15. [Preparation of the EPC and HEPC sterically stabilized doxorubicin liposomes and further studies on pharmacokinetics in rats].
Yu M; Wang Y; Shu G; Zhu Z; Fang S; Wang L
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Jun; 25(3):597-9. PubMed ID: 18693438
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia.
Myhren L; Nilssen IM; Nicolas V; Døskeland SO; Barratt G; Herfindal L
Eur J Pharm Biopharm; 2014 Sep; 88(1):186-93. PubMed ID: 24747809
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline antibiotics with high liposome entrapment: structural features and biological activity.
Perez-Soler R; Priebe W
Cancer Res; 1990 Jul; 50(14):4260-6. PubMed ID: 2194651
[TBL] [Abstract][Full Text] [Related]
18. Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo.
Versluis AJ; Rump ET; Rensen PC; van Berkel TJ; Bijsterbosch MK
J Pharmacol Exp Ther; 1999 Apr; 289(1):1-7. PubMed ID: 10086980
[TBL] [Abstract][Full Text] [Related]
19. [Cardiotoxic and myelosuppressive activity of various antitumor antibiotics of the anthracycline type in the rat].
Hoffmann H; Härtl A; Amlacher R; Güttner J; Fritsch RS
Arch Geschwulstforsch; 1983; 53(5):429-39. PubMed ID: 6651471
[TBL] [Abstract][Full Text] [Related]
20. Nanoerythrosome, a new derivative of erythrocyte ghost: preparation and antineoplastic potential as drug carrier for daunorubicin.
Lejeune A; Moorjani M; Gicquaud C; Lacroix J; Poyet P; Gaudreault R
Anticancer Res; 1994; 14(3A):915-9. PubMed ID: 8074493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
